Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization (AREEO), Karaj, Iran.
Arch Razi Inst. 2024 Apr 30;79(2):411-417. doi: 10.32592/ARI.2024.79.2.411. eCollection 2024 Apr.
Since around 100 years ago, the best treatment for millions of global snakebite victims has been polyclonal antivenoms. However, common antivenoms need continuous improvement to reduce rare, their side effects and get better performance. In the present study, Fab antivenom was produced through papain digestion of anti-cobra venom plasma, multi-step purification, and optimization, including ammonium sulfate precipitation and DEAE-cellulose column chromatography. Then, the existence of the corresponding Fab fragment antibody was seen and confirmed by SDS-PAGE method and double immunodifusion (Ouchterlony) test. In addition, the potency test in NIH laboratory mice revealed that each milliliter of the new Fab antivenom was able to neutralize 624 micrograms and (80LD) of cobra venom, which is about 15% more efficient than the primary plasma of the same concentration, and 1.57 times more effective than the cobra antivenom found in commercial hexavalent antivenom of Razi Institute. According to the findings, it seems that this new Fab antivenom can be used as a new candidate for treatment of cobra snakebite victims.
自大约 100 年前以来,治疗全球数百万名蛇伤患者的最佳方法一直是使用多克隆抗蛇毒血清。然而,普通抗蛇毒血清需要不断改进,以减少罕见的副作用,并提高性能。在本研究中,通过木瓜蛋白酶消化抗眼镜蛇毒血浆,经过多步纯化和优化,包括硫酸铵沉淀和 DEAE-纤维素柱层析,制备了 Fab 抗蛇毒血清。然后,通过 SDS-PAGE 方法和双免疫扩散(Ouchterlony)试验观察到并证实了相应 Fab 片段抗体的存在。此外,在 NIH 实验室小鼠中的效力测试表明,每毫升新的 Fab 抗蛇毒血清能够中和 624 微克和(80LD)的眼镜蛇毒液,其效力比相同浓度的原始血浆高约 15%,比拉齐研究所的商业六价抗蛇毒血清中的眼镜蛇抗蛇毒血清高 1.57 倍。根据这些发现,这种新的 Fab 抗蛇毒血清似乎可以用作治疗眼镜蛇咬伤患者的新候选药物。